ArticleInternational journal of nanomedicine2025
Artificial Cell-Derived Vesicles: Extracellular Vesicle Mimetics for Chondrocyte Restoration in TMJOA Therapy.
Article in International journal of nanomedicine, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 4 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
4 citing papers in PubMed.
- Immuno-Mechanical Signaling Network Integration in Temporomandibular Joint Pathology: A TMID Conceptual Framework.International journal of molecular sciences · 2026Review
- M1 macrophage-derived migrasomes ameliorate temporomandibular joint osteoarthritis via autophagy.Journal of nanobiotechnology · 2026Article
- A Bibliometric Analysis of Strategies for Atherosclerosis Treatment with Organic Nanoparticles.Pharmaceutics · 2025Review
- Engineered Extracellular Vesicles for Cartilage Regeneration: Bridging Biological Complexity to Clinical Precision.Avicenna journal of medical biotechnologyReview
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
10 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Purpose: Cartilage repair in temporomandibular joint osteoarthritis (TMJOA) remains a clinical challenge. Despite the strong repair potential of extracellular vesicles (EVs), their clinical use is constrained by yield and purification issues. This study explores artificial cell-derived vesicles (ACDVs) as a novel acellular strategy for cartilage repair, providing a promising alternative to EVs. Methods: EVs and ACDVs were isolated from umbilical cord mesenchymal stem cells, and their particle number and protein yield were compared. Mandibular condylar chondrocytes (MCCs) were treated with EVs/ACDVs after IL-1β stimulation to assess their effects on MCC apoptosis, proliferation, migration, and chondrogenic differentiation. Transcriptomic analysis was conducted to explore the therapeutic mechanisms of ACDVs. In a rat TMJOA model, local ACDV injection was evaluated for its effects on cartilage matrix synthesis and subchondral bone repair. Results: ACDVs resembled EVs in morphology and particle size, but exhibited significantly higher particle counts and protein yields. Efficiently internalized by MCCs, ACDVs effectively mitigated IL-1β-induced apoptosis, while promoting MCC proliferation, migration, and chondrogenic differentiation. This effect was likely mediated by the activation of genes involved in extracellular matrix synthesis. In a rat model of TMJOA, local ACDV injection ameliorated subchondral bone damage and stimulated cartilage matrix synthesis. Conclusion: This study demonstrates that ACDVs, generated by stepwise extrusion, are produced at significantly higher yields than EVs and show equal or superior efficacy in cartilage matrix repair. These findings endorse ACDVs as a promising alternative to EVs for disease therapy and drug delivery.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.